Cellectis S.A. American Depositary Shares

CLLS Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
CLLS Income Statement
CLLS Balance Sheet
CLLS Cash Flow
Congress Trading

Recent trades of CLLS by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
CLLS Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
CLLS Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
CLLS Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by CLLS's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard
Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
Corporate Lobbying

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Cellular immunotherapy for repetitive administration Nov. 19, 2024
  • Patent Title: Universal anti-cd22 chimeric antigen receptor engineered immune cells Nov. 05, 2024
  • Patent Title: Engineering wheat with increased dietary fiber Jun. 18, 2024
  • Patent Title: Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system Apr. 16, 2024
  • Patent Title: Universal anti-cd22 chimeric antigen receptor engineered immune cells Apr. 02, 2024
  • Patent Title: Cd123 specific chimeric antigen receptors for cancer immunotherapy Mar. 05, 2024
  • Patent Title: Engineered immune cells resistant to tumor microenvironment Feb. 20, 2024
  • Patent Title: Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy Feb. 06, 2024
  • Patent Title: Targeted gene insertion for improved immune cells therapy Jan. 16, 2024
  • Patent Title: Method for generating t-cells compatible for allogenic transplantation Nov. 21, 2023
  • Patent Title: Sequence specific reagents targeting ccr5 in primary hematopoietic cells Sep. 26, 2023
  • Patent Title: Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells Jul. 04, 2023
  • Patent Title: Universal chimeric antigen receptor t cells specific for cd22 Jul. 04, 2023
  • Patent Title: Compact scaffold of cas9 in the type ii crispr system Jun. 27, 2023
  • Patent Title: Sequential gene editing in primary immune cells Jun. 13, 2023
  • Patent Title: Canola with high oleic acid Apr. 11, 2023
  • Patent Title: Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy Mar. 14, 2023
  • Patent Title: Mutant Feb. 14, 2023
  • Patent Title: Method for making nicotiana plants with mutations in xylt and fuct alleles using rare-cutting endonucleases Jan. 17, 2023
  • Patent Title: Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy Nov. 15, 2022
  • Patent Title: Alfalfa with reduced lignin composition Oct. 25, 2022
  • Patent Title: Sequential gene editing in primary immune cells Oct. 11, 2022
  • Patent Title: Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells Aug. 16, 2022
  • Patent Title: Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system Jun. 21, 2022
  • Patent Title: Methods for altering amino acid content in plants through frameshift mutations Apr. 26, 2022
  • Patent Title: Methods for engineering highly active t cell for immunotherapy Apr. 26, 2022
  • Patent Title: Methods for engineering allogeneic and highly active t cell for immunotherapy Apr. 19, 2022
  • Patent Title: Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells Mar. 15, 2022
  • Patent Title: Method to overcome dna chemical modifications sensitivity of engineered tale dna binding domains Jan. 11, 2022
  • Patent Title: Method for the generation of compact tale-nucleases and uses thereof Dec. 14, 2021
  • Patent Title: Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients Nov. 30, 2021
  • Patent Title: Tale-protein scaffolds and uses thereof Oct. 05, 2021
  • Patent Title: Cd19 specific chimeric antigen receptor and uses thereof Aug. 03, 2021
  • Patent Title: Anti-cll1 specific single-chain chimeric antigen receptors (sccars) for cancer immunotherapy May. 25, 2021
  • Patent Title: Cd19 specific chimeric antigen receptor and uses thereof May. 18, 2021
  • Patent Title: Chimeric antigen receptors with integrated controllable functions Apr. 27, 2021
  • Patent Title: Cd123 specific chimeric antigen receptors for cancer immunotherapy Apr. 27, 2021
  • Patent Title: Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation Jan. 19, 2021
  • Patent Title: Cd19 specific chimeric antigen receptor and uses thereof Dec. 29, 2020
  • Patent Title: Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system Dec. 22, 2020
  • Patent Title: Modifying messenger rna stability in plant transformations Nov. 17, 2020
  • Patent Title: Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells Nov. 17, 2020
  • Patent Title: Transcription activator-like effector (tale) fusion protein Oct. 27, 2020
  • Patent Title: Method of engineering chemotherapy drug resistant t-cells for immunotherapy Oct. 27, 2020
  • Patent Title: Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment Sep. 08, 2020
  • Patent Title: Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy Sep. 01, 2020
  • Patent Title: Ror1 (ntrkr1) specific chimeric antigen receptors for cancer immunotherapy Aug. 25, 2020
  • Patent Title: Anti-gd3 specific chimeric antigen receptors for cancer immunotherapy Aug. 25, 2020
  • Patent Title: Tevi chimeric endonuclease and their preferential cleavage sites Aug. 11, 2020
  • Patent Title: Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation Jul. 14, 2020
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of CLLS in WallStreetBets Daily Discussion

CLLS News

Recent insights relating to CLLS

CNBC Recommendations

Recent picks made for CLLS stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CLLS

CLLS Top Shareholders
Shareholder
Shares Held
CLLS Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

CLLS Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view CLLS Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top